<DOC>
	<DOCNO>NCT01971203</DOCNO>
	<brief_summary>The primary objective study determine whether quetiapine extended-release combination cognitive behavioral therapy ( CBT ) effective CBT plus placebo treat depressive anxiety symptom patient major depression generalize anxiety disorder . Approximately 64 individual ( adult 18-65 ) randomly assign treatment group 16 week . Weekly CBT session conduct last 45 minute weekly visit study psychiatrist last 20 minute medication discuss . Both clinician administer self-report measure use compare group 16 week .</brief_summary>
	<brief_title>Efficacy Extended-release Quetiapine ( Seroquel XR ) Adjunctive Therapy Cognitive Behavioral Therapy Treat</brief_title>
	<detailed_description>This study evaluate efficacy quetiapine extended-release adjunctive therapy cognitive behavioral therapy ( CBT ) compare CBT plus placebo treatment patient comorbid major depression generalize anxiety disorder . We also evaluate quality life patient comorbid MDD/GAD , response remission rate treatment group , change sleep quality , tolerability adjunctive quetiapine CBT .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent A diagnosis major depression ( single episode recurrent ) generalize anxiety disorder Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) Females and/or male age 18 65 year Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrollment Able understand comply requirement study Pregnancy lactation Any history psychosis , bipolar disorder , schizophrenia , eat disorder OCD Imminent risk suicide danger self others Known intolerance lack response quetiapine fumarate , judge investigator Use follow cytochrome P450 3A4 inhibitor 14 day precede enrollment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir Use follow cytochrome P450 inducers 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomization Substance alcohol dependence enrollment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion Substance abuse DSMIV criterion within 6 month prior enrollment Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e.g . diabetes , angina pectoris , hypertension ) judge investigator Involvement planning conduct study Previous enrollment randomization treatment present study Participation another drug trial within 4 week prior enrollment study long accordance local requirement A patient Diabetes Mellitus ( DM )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>seroquel XR</keyword>
	<keyword>quetiapine XR</keyword>
	<keyword>major depression</keyword>
	<keyword>generalize anxiety disorder</keyword>
	<keyword>CBT</keyword>
	<keyword>co-morbid MDD</keyword>
</DOC>